甲状腺未分化癌靶向药物研究进展

doi:10.16139/j.1007-9610.2018.02.018

摘要/Abstract

中图分类号:

R736.1

刘颖, 张生来. 甲状腺未分化癌靶向药物研究进展[J]. 外科理论与实践, 2018, 23(02): 169-172.

[1] Lim H, Devesa SS, Sosa JA, et al.Trends in thyroid cancer incidence and mortality in the United States, 1974-2013[J]. JAMA,2017,317(13):1338-1348.
[2] Wendler J, Kroiss M, Gast K, et al.Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany[J]. Eur J Endocrinol,2016,175(6):521-529.
[3] Segerhammar I, Larsson C, Nilsson IL, et al.Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution[J]. J Surg Oncol,2012, 106(8):981-986.
[4] Ranganath R, Shah MA, Shah AR.Anaplastic thyroid cancer[J]. Curr Opin Endocrinol Diabetes Obes,2015,22(5):387-391.
[5] Smallridge RC, Ain KB, Asa SL, et al.American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer[J]. Thyroid,2012,22(11):1104-1139.
[6] Landa I, Ibrahimpasic T, Boucai L, et al.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers[J]. J Clin Invest,2016,26(3):1052-1066.
[7] Smallridge RC, Marlow LA, Copland JA.Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies[J]. Endocr Relat Cancer,2009,16(1):17-44.
[8] Jeon MJ, Chun SM, Kim D, et al.Genomic alterations of anaplastic thyroid carcinoma detected by targeted massive parallel sequencing in a BRAF(V600E) mutation-prevalent area[J]. Thyroid,2016,26(5):683-690.
[9] Liu Z, Hou P, Ji M, et al.Highly prevalent genetic altera-tions in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers[J]. J Clin Endocrinol Metab,2008,93(8):3106-3116.
[10] Lee J, Hwang JA, Lee EK.Recent progress of genome study for anaplastic thyroid cancer[J]. Genomics Inform,2013,11(2):68-75.
[11] Ensinger C, Spizzo G, Moser P, et al.Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas[J]. Ann N Y Acad Sci,2004,1030:69-77.
[12] Arora A, Scholar EM.Role of tyrosine kinase inhibitors in cancer therapy[J]. J Pharmacol Exp Ther,2005,315(3):971-979.
[13] Kim S, Yazici YD, Calzada G, et al.Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice[J]. Mol Cancer Ther,2007,6(6):1785-1792.
[14] Brose MS, Nutting CM, Jarzab B, et al.Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet,2014,384(9940):319-328.
[15] Savvides P, Nagaiah G, Lavertu P, et al.Phase Ⅱ trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid[J]. Thyroid,2013,23(5):600-604.
[16] Ha HT, Lee JS, Urba S, et al.A phase Ⅱ study of imatinib in patients with advanced anaplastic thyroid cancer[J]. Thyroid,2010,20(9):975-980.
[17] Xu CF, Xue Z, Bing N, et al.Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer[J]. Ann Oncol,2012,23(9):2470-2471.
[18] Bible KC, Suman VJ, Menefee ME, et al.A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer[J]. J Clin Endocrinol Metab,2012,97(9):3179-3184.
[19] McLarnon A. Thyroid cancer: Pazopanib alone is not effective against anaplastic thyroid cancer[J]. Nat Rev Endocrinol,2012,8(10):565.
[20] Isham CR, Bossou AR, Negron V, et al. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer[J]. Sci Transl Med,2013,5(166):166ra3.
[21] Miyake H, Miyazaki A, Imai S, et al.Early tumor shrinka-ge under treatment with first-line tyrosine kinase inhibitors as a predictor of overall survival in patients with metastatic renal cell carcinoma: a retrospective multi-institutional study in Japan[J]. Target Oncol,2016,11(2):175-182.
[22] Di Desidero T, Fioravanti A, Orlandi P, et al.Antiproli-ferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1[J]. J Clin Endocrinol Metab,2013,98(9):E1465-E1473.
[23] Bikas A, Kundra P, Desale S, et al.Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer[J]. Eur J Endocrinol,2016,174(3):373-380.
[24] Glen H, Mason S, Patel H, et al.E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion[J]. BMC Cancer,2011,11:309.
[25] Schlumberger M, Tahara M, Wirth LJ, et al.Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med,2015,372(7):621-630.
[26] Takahashi S, Tahara M, Kiyota N, et al. Phase Ⅱ study of lenvatinib(LEN), a multi-targeted tyrosine kinase inhibitor, in patients(PTS) with all histologic subtypes of advanced thyroid cancer[J]. Ann Oncol,2014,25(suppl 4): iv343-iv344.
[27] Tahara M, Kiyota N, Yamazaki T, et al.Lenvatinib for anaplastic thyroid Cancer[J]. Front Oncol,2017,7:25.
[28] Lim SM, Chang H, Yoon MJ, et al.A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes[J]. Ann Oncol,2013,24(12):3089-3094.
[29] Wagle N, Grabiner BC, van Allen EM, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer[J]. N Engl J Med,2014,371(15):1426-1433.
[30] Bollag G, Hirth P, Tsai J, et al.Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma[J]. Nature,2010,467(7315):596-599.
[31] Rosove MH, Peddi PF, Glaspy JA.BRAF V600E inhibition in anaplastic thyroid cancer[J]. N Engl J Med,2013, 368(7):684-685.
[32] Hyman DM, Puzanov I, Subbiah V, et al.Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations[J]. N Engl J Med,2015,373(8):726-736.
[33] Pennell NA, Daniels GH, Haddad RI, et al.A phase Ⅱ study of gefitinib in patients with advanced thyroid cancer[J]. Thyroid,2008,18(3):317-323.
[34] Tozer GM, Kanthou C, Baguley BC.Disrupting tumour blood vessels[J]. Nat Rev Cancer,2005,5(6):423-435.
[35] Dark GG, Hill SA, Prise VE, et al.Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature[J]. Cancer Res,1997,57(10):1829-1834.
[36] Sosa JA, Elisei R, Jarzab B, et al.Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma[J]. Thyroid,2014,24(2):232-240.
[37] Mooney CJ, Nagaiah G, Fu P, et al.A phase Ⅱ trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome[J]. Thyroid,2009,19(3):233-240.

甲状腺未分化癌靶向药物研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陆文婷　陈萍　卞薇薇. 冷敷面膜在激光治疗后疼痛护理中的作用[J]. 组织工程与重建外科杂志, 2022, 18(4): 342-.
[2]	冯秋实. 胆总管结石的微创治疗[J]. 外科理论与实践, 2022, 27(3): 185-188.
[3]	陈胜. 三镜联合微创治疗胆囊结石合并胆总管结石的方案选择[J]. 外科理论与实践, 2022, 27(3): 198-202.
[4]	宣呈杰, 卞冬生, 蒋咏梅, 陈宇菲, 金佳斌, 施咏梅. 营养治疗对减重术后身体成分及静息能量消耗的影响[J]. 外科理论与实践, 2022, 27(3): 244-248.
[5]	许梓枫, 宗雅萍, 陆爱国. 局部进展期结肠癌病人的新辅助治疗[J]. 外科理论与实践, 2022, 27(3): 266-270.
[6]	陈承坤, 郭伯敏, 邓先兆, 伍波, 樊友本. 甲状腺髓样癌的诊治现状[J]. 外科理论与实践, 2022, 27(3): 276-280.
[7]	陈佳佳　高敏哲　汪立　韩凌华　吴顺军　刘宁飞. 妇科相关肿瘤术后下肢淋巴水肿合并会阴部水肿的综合治疗初探[J]. 组织工程与重建外科杂志, 2022, 18(3): 242-.
[8]	戈成旺　林崴仪　唐枭伟　李磊　宋辉　蔡薇　沈干. 鼻翼退缩的研究进展[J]. 组织工程与重建外科杂志, 2022, 18(3): 284-.
[9]	聂萍　叶启程　王乐之　朱敏　王旭东. 从唇腭裂序列治疗理念的角度探讨医学生人文关怀意识的培养[J]. 组织工程与重建外科杂志, 2022, 18(3): 286-.
[10]	俞沁圆　王思圆　仲荣洲　李喆　黄国懂　魏雅洁　王斌. 先天性多发手部关节挛缩支具治疗的临床评价[J]. 组织工程与重建外科杂志, 2022, 18(2): 144-.
[11]	许佳　樊佳俊　韩冬　李馨　马燕红. 增生性瘢痕压力治疗的研究进展[J]. 组织工程与重建外科杂志, 2022, 18(2): 176-.
[12]	王小点　崔春晓　夏亮　冯少清　喜雯婧　肖文天　孟心娴　韩承尧　李科　章一新. 远红外线治疗妇科癌症术后下肢淋巴水肿的安全性研究[J]. 组织工程与重建外科杂志, 2022, 18(1): 19-.
[13]	汪立　刘宁飞　陈佳佳　高敏哲　韩凌华. 肢体慢性淋巴水肿CDT治疗后低弹力绷带使用时长对远期疗效的影响[J]. 组织工程与重建外科杂志, 2022, 18(1): 25-.
[14]	黄成　胡学庆. 淋巴水肿治疗的研究进展[J]. 组织工程与重建外科杂志, 2022, 18(1): 38-.
[15]	吴一文　王珊珊　张吕亚　肖喻　林洁　易庆阳　方木平 . 红蓝光照射联合阿达帕林凝胶治疗轻、中度痤疮[J]. 组织工程与重建外科杂志, 2022, 18(1): 74-.